By the end of 2017, 14 pharmaceutical (i.e. Cialis, main Viagra's competiror) patents will soon lapse. This means that similar generic drugs could also be found on the market, resulting in a large reduction in health spending. In 2016 the patent on the anti-cancer molecule Imatinib expired. As long as the patent was active the cost of a single pill was 15 euros. One-month therapy costed of 1800 euros. Thanks to the release of the generic drug in March 2017, healthcare expenses have dropped drastically.